Kyverna Therapeutics Presents Full One-Year Registrational Data for Miv-cel in Stiff Person Syndrome

Kyverna Therapeutics presented one-year registrational data for its lead product candidate, miv-cel, at the MS Toronto conference, showing sustained clinical benefits in treating stiff person syndrome. The company plans to complete a rolling Biologics License Application (BLA) submission for miv-cel by the fourth quarter of 2026. If approved, miv-cel could become the first CAR T-cell therapy for an autoimmune disease.